- $6.23m
- $1.69m
- $81.00m
- 62
- 79
- 53
- 70
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.81 | ||
| PEG Ratio (f) | 0.01 | ||
| EPS Growth (f) | 801.87% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.2 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 11.74 | ||
| Price to Sales | 0.09 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -17.89% | ||
| Return on Equity | -18.06% | ||
| Operating Margin | -13.57% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 27.63 | 65.63 | 96.67 | 107.4 | 81 | 67.1 | 72.57 | 61.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +90.28 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Directors
- Joshua Disbrow CHM (46)
- Mark Oki CFO (52)
- Jerry McLaughlin DRC (53)
- Gary Cantrell IND (66)
- Carl Dockery IND (58)
- John Donofrio IND (53)
- Beth Hecht IND (57)
- Michael Macaluso IND (69)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 8th, 2015
- Public Since
- October 20th, 2017
- No. of Shareholders
- 187
- No. of Employees
- 99
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 6,169,953
- Address
- 7900 E. Union Avenue, Suite 920, DENVER, 80237
- Web
- https://aytubio.com/
- Phone
- +1 7204376580
- Auditors
- GRANT THORNTON LLP (US)
Upcoming Events for AYTU
Aytu Biopharma Inc Annual Shareholders Meeting
Aytu Biopharma Inc Annual Shareholders Meeting
Q4 2025 Aytu Biopharma Inc Earnings Release
Similar to AYTU
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Aytu Biopharma share price?
As of Today at 19:28 UTC, shares in Aytu Biopharma are trading at $1.01. This share price information is delayed by 15 minutes.
How has the Aytu Biopharma share price performed this year?
Shares in Aytu Biopharma last closed at $1.01 and the price had moved by -64.85% over the past 365 days. In terms of relative price strength the Aytu Biopharma share price has underperformed the S&P500 Index by -66.94% over the past year.
What are the analyst and broker recommendations for Aytu Biopharma?
The overall consensus recommendation for Aytu Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aytu Biopharma dividend yield?
Aytu Biopharma does not currently pay a dividend.
Does Aytu Biopharma pay a dividend?
Aytu Biopharma does not currently pay a dividend.
When does Aytu Biopharma next pay dividends?
Aytu Biopharma does not currently pay a dividend.
How do I buy Aytu Biopharma shares?
To buy shares in Aytu Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aytu Biopharma?
As of the previous close price of $1.01, shares in Aytu Biopharma had a market capitalisation of $6.23m.
Where are Aytu Biopharma shares listed?
Here are the trading details for Aytu Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AYTU
What kind of share is Aytu Biopharma?
Based on an overall assessment of its quality, value and momentum Aytu Biopharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aytu Biopharma share price forecast for 2025?
The analyst consensus target price for shares in Aytu Biopharma is $8.00. That is 692% above the last closing price of $1.01.
Analysts covering Aytu Biopharma currently have a consensus Earnings Per Share (EPS) forecast of $0.72 for the next financial year.
Find out moreWhat is the trend in the Aytu Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aytu Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -51.12%.
As of the last closing price of $1.01, shares in Aytu Biopharma were trading -46.93% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aytu Biopharma PE Ratio?
The Aytu Biopharma PE ratio based on its reported earnings over the past 12 months is 0.81. The shares last closed at $1.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aytu Biopharma?
Aytu Biopharma's management team is headed by:
- Joshua Disbrow - CHM
- Mark Oki - CFO
- Jerry McLaughlin - DRC
- Gary Cantrell - IND
- Carl Dockery - IND
- John Donofrio - IND
- Beth Hecht - IND
- Michael Macaluso - IND